FGFR2 Mutations and IDH1 Real-World Data Suggests Caution with Immunotherapy in Specific mBTC – ASCO GI Dr. Richard Kim, MD Moffitt Cancer Center Gastrointestinal 3 Mins Read In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP) via liquid biopsy has become…
TIBSOVO’s Potential: Susan Pandya, MD, on FDA Priority Review for IDH1-Mutated MDS Acute Myelogenous Leukemia 1 Min Read In the interview, Susan Pandya, MD, Vice President of Clinical Development at Servier Pharmaceuticals, discusses the pivotal FDA acceptance and…
Amir T. Fathi MD [slides]- IDH 1/2-Mutant AML Treatment Acute Myelogenous Leukemia 1 Min Read Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join…
